Advanced search×

Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain.

Gary J GJ Vorsanger, Jim J Xiang, Theophilus J TJ Gana, Maria Luz G ML Pascual, and R Rosanna B RR Fleming

J Opioid Manag 4(2):87-97 (2008) PMID 18557165

This study evaluated the safety and efficacy of tramadol ER 300 mg and 200 mg versus placebo once daily in the treatment of chronic low back pain, using an open-label run-in followed by, without washout, a randomized controlled study design.

Version: za2963e q8zab q8zb9 q8zcd q8zd2 q8zee q8zf4 q8zg7
Buy PDF

Similar articles you may find interesting…

  1. Weight function approach to study a crack propagating along a bimaterial interface under asymmetric loading in orthotropic solids
    L Pryce, L Morini, and G Mishuris

    arXiv:1305.0486 [math-ph] 2 May 2013

    We show the significance of the asymmetry of the loading for computing the Energy release rate....
    View PDF
  2. The C- and N-terminal STIM1 binding sites on Orai1 are required for both trapping and gating CRAC channels.
    Beth A McNally, Agila Somasundaram, and Murali Prakriya

    J Physiol (2013) PMID 23613525

    We find that a variety of mutations in the N-terminal site impair the binding of Orai1 to STIM1 and to the soluble CRAC activation domain (CAD). Gating could be restored in several N- and C-terminal point mutants by directly tethering CAD to Orai1 (Orai1-SS channels), indicating that the loss of gat...
    Buy PDF
  3. Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate.
    Benno Roesch, Mary E Corcoran, and James Ermer

    Drugs R D (2013) PMID 23615868

    In healthy adults, coadministration of GXR and LDX did not result in a clinically meaningful pharmacokinetic DDI compared with either treatment alone. No unique TEAEs were observed with coadministration of GXR and LDX compared with either treatment alone....
    Buy PDF